Publications by authors named "Carmen Hernandez-Leon"
Article Synopsis
- Prognostic biomarkers are important for understanding sporadic desmoid tumors (DT) due to their unpredictable nature; this study focused on gene expression differences between DTs located in the thoracic versus abdominal wall.
- A retrospective analysis of 197 sporadic DT patients showed significant relationships between relapse-free survival (RFS) and factors like tumor size, location, and specific gene mutations, notably the CTNNB1 T41A and S45F mutations.
- Results suggest that tumors in the abdominal wall have a better prognosis compared to extra-abdominal locations, with distinct gene expression profiles influencing cancer pathways related to their behavior and outcomes.
HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor progression and drug resistance. Here, we reported the prognostic/predictive value of HMGA1 for trabectedin in advanced soft-tissue sarcoma (STS) and the effect of inhibiting HMGA1 or the mTOR downstream pathway in trabectedin activity. The prognostic/predictive value of HMGA1 expression was assessed in a cohort of 301 STS patients at mRNA (n = 133) and protein level (n = 272), by HTG EdgeSeq transcriptomics and immunohistochemistry, respectively.
View Article and Find Full Text PDFBackground: We retrospectively investigated the role of (neo)adjuvant chemotherapy in patients with primary, localized angiosarcoma.
Methods: We selected all patients with primary, localized angiosarcoma, who had received radical surgery between January 2005 and December 2019 at 33 European sarcoma reference centers. The primary objective was to compare the outcome of patients who received (neo)adjuvant chemotherapy versus those who did not, in terms of overall survival (OS), disease-free survival (DFS) and distant metastasis-free survival (DMFS).
Article Synopsis
- Predictive biomarkers for trabectedin in advanced soft-tissue sarcomas (STS) remain an unmet need, with previous studies focusing on a limited number of DNA damage repair (DDR) genes.
- Through a retrospective study, a new six-gene predictive signature for trabectedin efficacy was developed by analyzing 118 DDR-related genes in 139 tumor samples, revealing significant differences in progression-free survival between high-risk and low-risk groups.
- The study identified potential new biomarkers for sensitivity (PARP3, CCNH) and resistance (DNAJB11, PARP1) to trabectedin, suggesting that targeting these genes could improve treatment outcomes.
Introduction: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Numerous studies have reported the association between GIST and other neoplasms.
Objectives: The aim of this study was to investigate the possible association between GIST and other tumors in a genetically isolated population.